BioHealth News Archive
GMU selects three finalists for $250M Institute for Digital InnovAtion | Virginia Business
George Mason University on Monday announced three development and property management firms as finalists to build and operate its proposed $250 million Institute for…
Read More
AstraZeneca taps Catalent for COVID-19 vaccine finishing, packaging at Italian plant | FiercePharma
British drugmaker AstraZeneca is shooting for the moon with its plan to produce 2 billion doses per year of a potential COVID-19 vaccine. To…
Read More
University of Maryland Medical System awarded $18.7 million federal grant to fight coronavirus – Baltimore Sun
The University of Maryland Medical System will receive more than $18.7 million in funding from the Federal Emergency Management Agency (FEMA) in the ongoing…
Read More
GSK gets FDA approval for HIV drug for children – MarketWatch
Shares of GlaxoSmithKline GSK, +0.36% were down 0.05% in premarket trading on Monday after the Food and Drug Administration late on Friday approved its…
Read More
Novavax Appoints Biotechnology Veteran David Mott to Board of Directors | Novavax Inc. – IR Site
GAITHERSBURG, Md., June 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today…
Read More
Advisory Board | Johns Hopkins Technology Ventures
The IDEA Board champions innovation and entrepreneurship across the Johns Hopkins University, providing the vision and strategy by which Johns Hopkins will bring the…
Read More
ITI Enters into License Agreement with Ichor to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001 – Immunomic Therapeutics
ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor Medical Systems (“Ichor”),…
Read More
Emmes Chosen as a Top Area Workplace
ROCKVILLE, Md., June 17, 2020 /PRNewswire/ -- Emmes today announced that it was selected as one of the best places to work in the greater…
Read More
GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance – Xconomy
GlaxoSmithKline got its first taste of synthetically lethal cancer therapies via an acquisition. Now it’s trying for a bigger bite of this emerging drug…
Read More
Royalty Pharma, drug firm that doesn’t develop drugs, shatters IPO record
Royalty Pharma, a business built on investing in other people’s medicines, raised $2.2 billion in a record IPO on Tuesday, and the early hours…
Read More
Sirnaomics and Precision NanoSystems Have Formed a Partnership | BioSpace
Developing and Manufacturing Novel RNAi drug Candidates Using Precision NanoSystems' NxGen™ Platform GAITHERSBURG, MD and VANCOUVER, BC, June 17, 2020 /PRNewswire/ - Sirnaomics Inc. (Sirnaomics)…
Read More
Rexahn and Ocuphire Enter into Definitive Merger Agreement :: Rexahn Pharmaceuticals, Inc. (REXN)
ROCKVILLE, Md. and FARMINGTON HILLS, Mich., June 17, 2020 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN) and Ocuphire Pharma, Inc., a privately-held clinical-stage…
Read More
Emergent Bio to invest $75M in Canton site (NYSE:EBS) | Seeking Alpha
Emergent BioSolutions (NYSE:EBS) will invest $75M in its Canton, Massachusetts facility, focused on the development and manufacturing of drug substance for live viral vaccines…
Read More
Emergent BioSolutions Adding Approximately 300 Jobs After New COVID-19 Vaccine Contracts
Business is booming for Emergent BioSolutions as it has assisted in the country’s push to create COVID-19 treatments and vaccines. Emergent is developing two…
Read More
Emergent BioSolutions Enters Viral Vector And Gene Therapy Arena – Contract Pharma
Emergent BioSolutions has unveiled plans to strengthen its contract development and manufacturing (CDMO) capabilities by expanding into viral vector and gene therapy. The company…
Read More